Resum
Idioma original | Anglès |
---|---|
Pàgines (de-a) | 579-588 |
Nombre de pàgines | 10 |
Revista | JAIDS Journal of Acquired Immune Deficiency Syndromes |
Volum | 78 |
Número | 5 |
DOIs | |
Estat de la publicació | Publicada - d’ag. 2018 |
SDG de les Nacions Unides
Aquest resultat contribueix als següents objectius de desenvolupament sostenible.
Accés al document
Altres arxius i enllaços
Fingerprint
Navegar pels temes de recerca de 'Body mass index and the risk of serious non-AIDS events and all-cause mortality in treated HIV-positive individuals: D:A:D Cohort analysis: Journal of Acquired Immune Deficiency Syndromes'. Junts formen un fingerprint únic.Com citar-ho
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: JAIDS Journal of Acquired Immune Deficiency Syndromes, Vol. 78, Núm. 5, 08.2018, pàg. 579-588.
Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts
TY - JOUR
T1 - Body mass index and the risk of serious non-AIDS events and all-cause mortality in treated HIV-positive individuals: D:A:D Cohort analysis
T2 - Journal of Acquired Immune Deficiency Syndromes
AU - Achhra, A.C.
AU - Sabin, C.
AU - Ryom, L.
AU - Hatleberg, C.
AU - Antonella D'Aminio, M.
AU - De Wit, S.
AU - Phillips, A.
AU - Pradier, C.
AU - Weber, R.
AU - Reiss, P.
AU - El-Sadr, W.
AU - Bonnet, F.
AU - Mocroft, A.
AU - Lundgren, J.
AU - Law, M.G.
AU - Torres, Ferran
N1 - Cited By :15 Export Date: 17 February 2022 CODEN: JJASF Correspondence Address: Achhra, A.C.; Kirby Institute, High Street, Australia; email: [email protected] Chemicals/CAS: abacavir, 136470-78-5, 188062-50-2; proteinase inhibitor, 37205-61-1 Funding details: 260694 Funding details: National Institutes of Health, NIH, 5U01AI042170-10, 5U01AI046362-03 Funding details: U.S. Food and Drug Administration, FDA Funding details: National Institute of Allergy and Infectious Diseases, NIAID, U01-AI069907 Funding details: Bristol-Myers Squibb, BMS Funding details: Pfizer Funding details: Janssen Research and Development, JRD Funding details: Gilead Sciences Funding details: AbbVie Funding details: Boehringer Ingelheim Funding details: Janssen Pharmaceuticals Funding details: Merck Sharp and Dohme, MSD Funding details: ViiV Healthcare Funding details: Cilag Funding details: Pfizer Australia, 148522 Funding details: GlaxoSmithKline Australia, GSK Funding details: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, SNF, 108787 Funding details: Danmarks Grundforskningsfond, DNRF Funding details: University of New South Wales, UNSW Funding details: Ministerie van Volksgezondheid, Welzijn en Sport, VWS Funding details: Agence Nationale de Recherches sur le Sida et les Hépatites Virales, ANRS Funding details: Fundación Emilio Soldevilla para la Investigación y el Desarrollo en Economía de la Empresa, FESIDE, FIPSE 3171/00 Funding details: INCLIVA Instituto de Investigación Sanitaria, FIS 99/0887 Funding text 1: Data on Adverse Events (D:A:D) Study was supported by a grant (Grant number DNRF126) from the Danish National Research Foundation (CHIP & PERSIMUNE); the Highly Active Antiretroviral Therapy Oversight Committee (HAARTOC), a collaborative committee with representation from academic institutions, the European Agency for the Evaluation of Medicinal Products, the United States Food and Drug Administration, the patient community, and pharmaceutical companies with licensed anti-HIV drugs in the European Union: AbbVie, Bristol-Myers Squibb, Gilead Sciences Inc., ViiV Healthcare, Merck & Co Inc., and Janssen Pharmaceuticals. Supported also by a grant from the Dutch Ministry of Health, Welfare and Sport through the Center for Infectious Disease Control of the National Institute for Public Health and the Environment to Stiching HIV Monitoring (ATHENA); by a grant from the Agence nationale de recherches sur le sida et les hépatites virales (ANRS, Action Coordonnée no.7, Cohortes) to the Aquitaine Cohort; The Australian HIV Observational Database (AHOD) is funded as part of the Asia Pacific HIV Observational Database, a program of The Foundation for AIDS Research, amfAR, and is supported in part by a grant from the U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) (Grant number U01-AI069907) and by unconditional grants from Merck Sharp & Dohme; Gilead Sciences; Bristol-Myers Squibb; Boehringer Ingelheim; Janssen-Cilag; and ViiV Healthcare. The Kirby Institute is funded by The Australian Government Department of Health and Ageing, and is affiliated with the Faculty of Medicine, The University of New South Wales; by grants from the Fondo de Investigación Sanitaria (Grant number FIS 99/0887) and Fundación para la Investigación y la Prevención del SIDA en Espanã (Grant number FIPSE 3171/00) to the Barcelona Antiretroviral Surveillance Study (BASS); by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (Grants number 5U01AI042170-10, 5U01AI046362-03) to the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA); by primary funding provided by the European Union’s Seventh Framework Programme for research, technological development and demonstration under EuroCoord Grant agreement no. 260694 and unrestricted grants by Bristol-Myers Squibb, Janssen R&D, Merck and Co. Inc., Pfizer Inc., and GlaxoSmithKline LLC [the participation of centers from Switzerland is supported by The Swiss National Science Foundation (Grant 108787)] to the EuroSIDA study; by unrestricted educational grants of AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Pfizer, and Janssen Pharmaceuticals to the Italian Cohort Naive to Antiretrovirals (The ICONA Foundation); and financed within the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation (Grant #148522) and by the SHCS research foundation. References: Koethe, J.R., Jenkins, C.A., Lau, B., Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada (2016) AIDS Res Hum Retroviruses, 32, pp. 50-58; Crum-Cianflone, N., Roediger, M.P., Eberly, L., Increasing rates of obesity among HIV-infected persons during the HIV epidemic (2010) PLoS One, 5, p. e10106; (2006) Obesity and Overweight, , http://www.who.int/mediacentre/factsheets/fs311/en/, World Health Organization (WHO) Accessed August 1, 2017; Renehan, A.G., Tyson, M., Egger, M., Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies (2008) Lancet, 371, pp. 569-578; Berringtonde Gonzalez, A., Hartge, P., Cerhan, J.R., Body-mass index and mortality among 1.46 million white adults (2010) N Engl J Med, 363, pp. 2211-2219; Sabin, C.A., Reiss, P., Epidemiology of ageing with HIV: What can we learn from cohorts (2017) AIDS, 31, pp. S121-S128; Koethe, J.R., Jenkins, C.A., Shepherd, B.E., An optimal body mass index range associated with improved immune reconstitution among HIVinfected adults initiating antiretroviral therapy (2011) Clin Infect Dis, 53, pp. 952-960; Achhra, A.C., Mocroft, A., Reiss, P., Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: The D:A:D study (2016) HIV Med, 17, pp. 255-268; Koethe, J.R., Jenkins, C.A., Turner, M., Body mass index and the risk of incident noncommunicable diseases after starting antiretroviral therapy (2015) HIV Med, 16, pp. 67-72; Friis-Moller, N., Reiss, P., Sabin, C.A., Class of antiretroviral drugs and the risk of myocardial infarction (2007) N Engl J Med, 356, pp. 1723-1735. , For the D:A:D Study Group; Kyrgiou, M., Kalliala, I., Markozannes, G., Adiposity and cancer at major anatomical sites: Umbrella review of the literature (2017) BMJ, 356, p. J477; Textor, J., Hardt, J., Knuppel, S., DAGitty: A graphical tool for analyzing causal diagrams (2011) Epidemiology, 22, p. 745; Ryom, L., Lundgren, J.D., Ross, M., Renal impairment and cardiovascular disease in HIV-positive individuals: The D:A:D study (2016) J Infect Dis, 214, pp. 1212-1220; Cockcroft, D.W., Gault, M.H., Prediction of creatinine clearance from serum creatinine (1976) Nephron, 16, pp. 31-41; Petoumenos, K., Law, M.G., Smoking, alcohol and illicit drug use effects on survival in HIV-positive persons (2016) Curr Opin HIV AIDS, 11, pp. 514-520; Petoumenos, K., Worm, S., Reiss, P., Rates of cardiovascular disease following smoking cessation in patients with HIV infection: Results from the D:A:D study (2011) HIV Med, 12, pp. 412-421; Flegal, K.M., Kit, B.K., Orpana, H., Association of all-cause mortality with overweight and obesity using standard body mass index categories: A systematic review and meta-analysis (2013) JAMA, 309, pp. 71-82; Hainer, V., Aldhoon-Hainerova, I., Obesity paradox does exist (2013) Diabetes Care, 36, pp. S276-S281; Romero-Corral, A., Montori, V.M., Somers, V.K., Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: A systematic review of cohort studies (2006) Lancet, 368, pp. 666-678; Filardo, G., Hamilton, C., Hamman, B., Categorizing BMI may lead to biased results in studies investigating in-hospital mortality after isolated CABG (2007) J Clin Epidemiol, 60, pp. 1132-1139; Sharma, A., Hoover, D.R., Shi, Q., Relationship between body mass index and mortality in HIV-infected HAART users in the women's interagency HIV study (2015) PLoS One, 10, p. e0143740
PY - 2018/8
Y1 - 2018/8
N2 - Background: The relationship between body mass index (BMI) [weight (kg)/height (m 2)] and serious non-AIDS events is not well understood. Methods: We followed D:A:D study participants on antiretroviral therapy from their first BMI measurement to the first occurrence of the endpoint or end of follow-up (N = 41,149 followed for 295,147 person-years). The endpoints were cardiovascular disease (CVD); diabetes; non-AIDS-defining cancers (NADCs) and BMI-NADCs (cancers known to be associated with BMI in general population); and all-cause mortality. Using Poisson regression models, we analyzed BMI as time-updated, lagged by 1 year, and categorized at: 18.5, 23, 25, 27.5, and 30 kg/m 2. Results: Participants were largely male (73%) with the mean age of 40 years (SD 9.7) and baseline median BMI of 23.3 (interquartile range: 21.2-25.7). Overall, BMI showed a statistically significant J-shaped relationship with the risk of all outcomes except diabetes. The relative risk (RR) for the BMI of 30 (95% confidence interval) compared with 23-25, respectively, was as follows: CVD: 1.46 (1.15-1.84) and 1.31 (1.03-1.67); NADCs: 1.78 (1.39-2.28) and 1.17 (0.88-1.54); and "BMI-NADCs": 1.29 (0.66-2.55) and 1.92 (1.10-3.36). For all-cause mortality, there was an interaction by sex (P < 0.001): RR in males: 2.47 (2.12-2.89) and 1.21 (0.97-1.50); and in females: 1.60 (1.30-1.98) and 1.02 (0.74-1.42). RR remained around 1 for intermediate categories of BMI. The risk of diabetes linearly increased with increasing BMI (P < 0.001). Conclusions: Risk of CVD, a range of cancers, and all-cause mortality increased at low BMI ( 30 with a relatively low risk at BMI of 23-25 and 25-30. High BMI was also associated with risk of diabetes. © 2018 Wolters Kluwer Health, Inc. All rights reserved.
AB - Background: The relationship between body mass index (BMI) [weight (kg)/height (m 2)] and serious non-AIDS events is not well understood. Methods: We followed D:A:D study participants on antiretroviral therapy from their first BMI measurement to the first occurrence of the endpoint or end of follow-up (N = 41,149 followed for 295,147 person-years). The endpoints were cardiovascular disease (CVD); diabetes; non-AIDS-defining cancers (NADCs) and BMI-NADCs (cancers known to be associated with BMI in general population); and all-cause mortality. Using Poisson regression models, we analyzed BMI as time-updated, lagged by 1 year, and categorized at: 18.5, 23, 25, 27.5, and 30 kg/m 2. Results: Participants were largely male (73%) with the mean age of 40 years (SD 9.7) and baseline median BMI of 23.3 (interquartile range: 21.2-25.7). Overall, BMI showed a statistically significant J-shaped relationship with the risk of all outcomes except diabetes. The relative risk (RR) for the BMI of 30 (95% confidence interval) compared with 23-25, respectively, was as follows: CVD: 1.46 (1.15-1.84) and 1.31 (1.03-1.67); NADCs: 1.78 (1.39-2.28) and 1.17 (0.88-1.54); and "BMI-NADCs": 1.29 (0.66-2.55) and 1.92 (1.10-3.36). For all-cause mortality, there was an interaction by sex (P < 0.001): RR in males: 2.47 (2.12-2.89) and 1.21 (0.97-1.50); and in females: 1.60 (1.30-1.98) and 1.02 (0.74-1.42). RR remained around 1 for intermediate categories of BMI. The risk of diabetes linearly increased with increasing BMI (P < 0.001). Conclusions: Risk of CVD, a range of cancers, and all-cause mortality increased at low BMI ( 30 with a relatively low risk at BMI of 23-25 and 25-30. High BMI was also associated with risk of diabetes. © 2018 Wolters Kluwer Health, Inc. All rights reserved.
KW - AIDS
KW - all-cause mortality
KW - BMI
KW - HIV
KW - non-AIDS
KW - obesity
KW - abacavir
KW - antiretrovirus agent
KW - proteinase inhibitor
KW - RNA directed DNA polymerase inhibitor
KW - acquired immune deficiency syndrome
KW - adult
KW - adverse event
KW - all cause mortality
KW - antiretroviral therapy
KW - Article
KW - body mass
KW - cardiovascular disease
KW - cohort analysis
KW - correlation analysis
KW - diabetes mellitus
KW - female
KW - follow up
KW - human
KW - Human immunodeficiency virus infected patient
KW - Human immunodeficiency virus infection
KW - longitudinal study
KW - major clinical study
KW - male
KW - malignant neoplasm
KW - observational study
KW - outcome assessment
KW - Poisson distribution
KW - priority journal
KW - regression analysis
KW - risk assessment
KW - risk factor
KW - sex
KW - statistical analysis
KW - statistical significance
KW - cause of death
KW - complication
KW - middle aged
KW - mortality
KW - neoplasm
KW - pathophysiology
KW - Adult
KW - Body Mass Index
KW - Cardiovascular Diseases
KW - Cause of Death
KW - Cohort Studies
KW - Diabetes Mellitus
KW - Female
KW - HIV Infections
KW - Humans
KW - Male
KW - Middle Aged
KW - Neoplasms
KW - Poisson Distribution
UR - http://insights.ovid.com/crossref?an=00126334-201808150-00014
U2 - 10.1097/QAI.0000000000001722
DO - 10.1097/QAI.0000000000001722
M3 - Article
VL - 78
SP - 579
EP - 588
JO - JAIDS Journal of Acquired Immune Deficiency Syndromes
JF - JAIDS Journal of Acquired Immune Deficiency Syndromes
IS - 5
ER -